12.07.2015 Views

PDF, Patent Landscape Report on Atazanavir - WIPO

PDF, Patent Landscape Report on Atazanavir - WIPO

PDF, Patent Landscape Report on Atazanavir - WIPO

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

EARLIEST PRIORITY COUNTRYDetermining the priority country (country of first filing) is the easiest way to get an idea ofwhere inventi<strong>on</strong>s were made, and typically corresp<strong>on</strong>ds to a company locati<strong>on</strong>. Globalcompanies may file in multiple countries if they have R&D facilities in each place. Most ofthe inventi<strong>on</strong>s in this collecti<strong>on</strong> were filed first in the US, and 70% of them were also filed ina PCT office (or have a priority in a PCT Office). This is partly explained because thepharmaceutical industry in general favors PCT filing. By examining the applicati<strong>on</strong> numberof a PCT filing, the country of origin of the applicati<strong>on</strong> can be determined, and Figure 15also shows the country of origin (receiving office) for the PCT applicati<strong>on</strong>s.Observati<strong>on</strong>s include: a) relatively low participati<strong>on</strong> in this technical field by Japanesecompanies, whether measured through in-country priority filings or PCT filings, and b)noticeable but not large participati<strong>on</strong> by India. The numbers of families that have grants in<strong>on</strong>e or more authorities are also shown, and is 29% for the US and 35% for the EPO. Thegrant of a patent implies novelty, but the grant rate statistic is affected by the age of theinventi<strong>on</strong>, since young applicati<strong>on</strong>s are not expected to grant in a time shorter than thenormal pendency period.Figure 15. Priority Country Informati<strong>on</strong>22

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!